CoQ10 coenzyme Q-10 and Imatinib Mesylate

• Generic Name: ubiquinone
• Dosage Forms: n.a.
• Other Brand Names: Coenzyme Q10, CoQ10, elppa CoQ10, LiQsorb, Q-Sorb Co Q-10, QuinZyme, Co-Q10, NutraDrops, Liquid Co-Q10, Co Q-10, Coenzyme Q10, LiQ-10

CoQ10 is a vitamin-like substance that is made naturally in the body. This medicine is also known as Coenzima, Ubidcarenone, Ubidécarénone, and Ubiquinol.

CoQ10 is likely effective in alternative medicine as an aid in treating coenzyme Q-10 deficiency, or reducing the symptoms of mitochondrial disorders (conditions that affect energy-production in the cells of the body).

CoQ10 is also possibly effective in preventing migraine headaches, lowering blood pressure, preventing a second heart attack, or slowing the progression of early Parkinson's disease. This medicine is also possibly effective in improving symptoms in people with congestive heart failure, nerve problems caused by diabetes, Huntington's disease, muscular dystrophy, or macular degeneration (age-related vision loss).

CoQ10 has also been used to treat Alzheimer's disease, high cholesterol, or amyotrophic lateral sclerosis (Lou Gehrig's disease). However, research has shown that this medicine may not be effective in treating these conditions.

Research also has shown that CoQ10 is not likely to be effective in increasing athletic performance.

Other uses not proven with research have included treating asthma, COPD, cancer, diabetes, certain heart problems, fibromyalgia, hepatitis C, kidney problems, high blood pressure during pregnancy, muscle problems caused by taking "statin" cholesterol medicine, and other conditions.

CoQ10 is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

CoQ10 may also be used for purposes not listed in this product guide.

• Generic Name: imatinib
• Dosage Forms: n.a.
• Other Brand Names: Gleevec

First-line treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) CML in adult and pediatric patients who are in the chronic phase of the disease (designated an orphan drug by FDA for this use); follow-up is limited.

Second-line treatment of Ph+ CML in adults who are in blast crisis, in the accelerated phase, or in the chronic phase of the disease after failure of interferon alfa therapy (designated an orphan drug by FDA for this use).

Second-line treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplantation or who are resistant to interferon alfa therapy.

Efficacy in pediatric patients determined based on overall hematologic and/or cytogenetic response rates; actual clinical benefits (e.g., decrease in disease-related symptoms, increase in survival) not adequately studied.

Treatment of relapsed or refractory Ph+ ALL in adults (designated an orphan drug by FDA for this use).

Treatment of MDS or MPD associated with gene rearrangements of platelet-derived growth factor receptor (PDGFR) in adults (designated an orphan drug by FDA for this use).

Treatment of aggressive systemic mastocytosis (ASM) in adults who lack the D816V c-Kit mutation or in whom c-Kit mutational status is unknown (designated an orphan drug by FDA for this use).

Ineffective for ASM with the D816V c-Kit mutation; other therapy is indicated.

Has not been shown to be effective in patients with less aggressive forms of SM. Therefore, not recommended for use in patients with cutaneous mastocytosis, indolent SM (smoldering SM or isolated bone marrow mastocytosis), SM with an associated clonal hematologic non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma, or extracutaneous mastocytoma.

Treatment of HES and/or CEL in adults who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion), patients who are negative for FIP1L1-PDGFRα fusion kinase, or patients in whom expression of FIP1L1-PDGFRα fusion kinase is unknown (designated an orphan drug by FDA for this use).

Treatment of unresectable, recurrent, and/or metastatic DFSP in adults (designated an orphan drug by FDA for this use).

Treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant GIST (designated an orphan drug by FDA for this use).

Efficacy determined based on objective response rates; actual clinical benefits (e.g., decrease in disease-related symptoms, increase in survival) not adequately studied.